🏛️ Verified NIH Record • Updated 2026-08-10
ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) (NCT05601752)
A Phase 2, Open-Label, Randomized, Non-Comparative Clinical Trial of ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in Subjects With Recurrent Ovarian Cancers
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: USWM CT, LLC
🩺 Plain-English Summary (8th-Grade Level)
This is a phase 2, open-label, randomized, non-comparative clinical trial to evaluate the clinical outcome of ADP A2M4CD8 as monotherapy and in combination treatment with nivolumab in human leukocyte antigen (HLA) A2+ subjects with recurrent ovarian cancer positive for MAGE-A4.
Who can join: Review the eligibility criteria below.
Location: Honor Health — Scottsdale, Arizona
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (23 Sites)
- Honor Health — Scottsdale, Arizona
- City of Hope — Duarte, California
- Augusta University — Augusta, Georgia
- Karmanos Cancer Institute — Detroit, Michigan
- Rutgers Cancer Institute of NJ — New Brunswick, New Jersey
- Cleveland Clinic Foundation — Cleveland, Ohio
- University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
- Avera Cancer Institute — Sioux Falls, South Dakota
- Swedish Cancer Institute — Seattle, Washington
- University Health Network (Princess Margaret Cancer Center) — Toronto, Ontario
- Institut de Cancerologie des Hospices Civils de Lyon — Pierre-Bénite, Lyon
- Centre Leon-Berard — Lyon,
- Institut de Cancerologie de Strasbourg — Strasbourg,
- Institut Gustave Roussy — Villejuif,
- Vall d'Hebron Unversity Hospital — Barcelona,
- Clinica Universidad de Navarra — Madrid,
- Hospital Universitario Ramón y Cajal — Madrid,
- Hospital Universitario Fundación Jiménez Díaz — Madrid,
- Hospital Universitario 12 de Octubre — Madrid,
- Centro Oncologico Clara Campal — Madrid,
- Hospotal Clinico Universitario de Valencia — Valencia,
- University College of London Hospital — London,
- The Christie Hospital — Manchester,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ovarian Cancer
- Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy — New York, New York
- Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer — Pittsburgh, Pennsylvania
- Trial on Radical Upfront Surgery in Advanced Ovarian Cancer — New York, New York
- Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) — Duarte, California
- Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) — Little Rock, Arkansas
- NeoVax With Nivolumab in Patients With Ovarian Cancer — Boston, Massachusetts
Explore by condition: All Ovarian Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.